ReviewInfectious diseases of poverty2017
Moving from control to elimination of schistosomiasis in sub-Saharan Africa: time to change and adapt strategies.
Review in Infectious diseases of poverty, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 5 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Effects of paediatric schistosomiasis control programmes in sub-Saharan Africa: A systematic review.PloS one · 2024Pooled it
- Historical overview and geographical distribution of neglected tropical diseases amenable to preventive chemotherapy in the Republic of the Congo: A systematic review.PLoS neglected tropical diseases · 2022Pooled it
- Core components, concepts and strategies for parasitic and vector-borne disease elimination with a focus on schistosomiasis: A landscape analysis.PLoS neglected tropical diseases · 2020Pooled it
- Pooled it
- Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs.Wellcome open research · 2020Pooled it
- Female genital schistosomiasis, human papilloma virus infection, and cervical cancer in rural Madagascar: a cross sectional study.Infectious diseases of poverty · 2023Trial
- Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.PLoS neglected tropical diseases · 2020Trial
- Evaluation of integrated interventions layered on mass drug administration for urogenital schistosomiasis elimination: a cluster-randomised trial.The Lancet. Global health · 2019Trial
- Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial.BMC infectious diseases · 2018Trial
- "We don't know schistosomiasis can affect the female reproductive system and increase the risk of HIV": A mixed-methods analysis reveals gaps in risk factor determinants and health consequences of female genital schistosomiasis in Southern Chad.PLoS neglected tropical diseases · 2026Article
- Molecular, parasitological and clinical diagnosis of female genital schistosomiasis: A diagnostic yield and comparative accuracy study using latent class analysis.Parasitology research · 2026Article
- Diagnostic competence and health worker knowledge of female genital schistosomiasis management in a rural Ghanaian district.PLoS neglected tropical diseases · 2026Article
- Host-specific platelet-activating factor acetylhydrolase selectively remodels diacylglycerophospholipids to control schistosome development.PLoS pathogens · 2026Article
- Biomphalaria pfeifferi infected with Schistosoma spp. in Kakamega and Bungoma counties, western Kenya confirms autochthonous transmission of intestinal schistosomiasis.PLoS neglected tropical diseases · 2026Article
- Sub-microscopic schistosomiasis and soil-transmitted helminths in school children: molecular diagnostic evidence and implications for disease elimination.Scientific reports · 2026Article
- Rapid identification of Biomphalaria spp. and diagnosis of Schistosoma mansoni infestation using MALDI-TOF mass spectrometry.PLoS neglected tropical diseases · 2026Article
- Community survey of the infection, intensity and risk factors associated with schistosomiasis and soil-transmitted helminthiasis in south-eastern Gabon.Scientific reports · 2026Article
- Prevalence of Schistosoma bovis and Schistosoma haematobium hybrids in endemic communities in Ghana.PloS one · 2026Article
- A multi-site laboratory evaluation of the MEDSCAN application for automated POC-CCA interpretation.Frontiers in parasitology · 2026Article
- Schistosomal Colitis as an Uncommon Cause of Hematochezia in a School-Aged Boy: A Case Report.Clinical medicine insights. Pediatrics · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is a water borne parasitic disease of global importance and with ongoing control the disease endemic landscape is changing. In sub-Saharan Africa, for example, the landscape is becoming ever more heterogeneous as there are several species of Schistosoma that respond in different ways to ongoing preventive chemotherapy and the inter-sectoral interventions currently applied. The major focus of preventive chemotherapy is delivery of praziquantel by mass drug administration to those shown to be, or presumed to be, at-risk of infection and disease. In some countries, regional progress may be uneven but in certain locations there are very real prospects to transition from control into interruption of transmission, and ultimately elimination. To manage this transition requires reconsideration of some of the currently deployed diagnostic tools used in surveillance and downward realignment of existing prevalence thresholds to trigger mass treatment. A key challenge will be maintaining and if possible, expanding the current donation of praziquantel to currently overlooked groups, then judging when appropriate to move from mass drug administration to selective treatment. In so doing, this will ensure the health system is adapted, primed and shown to be cost-effective to respond to these changing disease dynamics as we move forward to 2020 targets and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.